SANTA BARBARA, Calif., Sept. 8, 2022 /PRNewswire/ — Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced that the Company’s management will be participating in the 2022 Jeffries Innovation in Mental Health Summit. Bexson’s Chief Executive Officer, Gregg Peterson…


Previous articleMindMed Announces Positive Results from Collaborators’ Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal
Next articleAlgernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami